Is Vaxart a Buy?
In the early days of the pandemic, Vaxart (NASDAQ: VXRT) mesmerized investors after beginning development of a tablet-based, room-temperature-stable coronavirus vaccine. The stock subsequently soared to a multiyear high of $24.90 per share in February, becoming a ten-bagger over a 12 month period.
Fast-forward three months later, though, and the stock is down an astonishing 71% from its highs. What's behind Vaxart's massive roller coaster ride?
Image source: Getty Images.
Source Fool.com
